These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9734501)

  • 1. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report.
    Hodak SP; Moubarak JB; Rodriguez I; Gelfand MC; Alijani MR; Tracy CM
    Transplantation; 1998 Aug; 66(4):535-7. PubMed ID: 9734501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Impact of Different Immunosuppressive Drugs on QT and PR Intervals in Renal Transplant Patients.
    Ikitimur B; Cosansu K; Karadag B; Cakmak HA; Avci BK; Erturk E; Seyahi N; Ongen Z
    Ann Noninvasive Electrocardiol; 2015 Sep; 20(5):426-32. PubMed ID: 25367596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperglycemia and subsequent torsades de pointes with marked QT prolongation during refeeding.
    Nakashima T; Kubota T; Takasugi N; Kitagawa Y; Yoshida T; Ushikoshi H; Kawasaki M; Nishigaki K; Ogura S; Minatoguchi S
    Nutrition; 2017 Jan; 33():145-148. PubMed ID: 27544004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sublingual administration of tacrolimus in a renal transplant patient.
    Romero I; Jiménez C; Gil F; Escuin F; Ramirez E; Fudio S; Borobia A; Carcas A
    J Clin Pharm Ther; 2008 Feb; 33(1):87-9. PubMed ID: 18211623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haloperidol-induced torsade de pointes.
    O'Brien JM; Rockwood RP; Suh KI
    Ann Pharmacother; 1999 Oct; 33(10):1046-50. PubMed ID: 10534216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.
    Kao DP; Haigney MC; Mehler PS; Krantz MJ
    Addiction; 2015 Sep; 110(9):1468-75. PubMed ID: 26075588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual administration improves systemic exposure of tacrolimus in kidney transplant recipients: comparison with oral administration.
    Federico S; Carrano R; Sabbatini M; Nappi R; Russo L; Apicella L; Balletta MM; Santangelo M; Mosca T; Tarantino G; Capone D
    Eur J Clin Invest; 2016 Jul; 46(7):651-7. PubMed ID: 27240092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.
    Othong R; Devlin JJ; Kazzi ZN
    Clin Toxicol (Phila); 2015 May; 53(4):204-9. PubMed ID: 25706450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome.
    Halkin A; Roth A; Lurie I; Fish R; Belhassen B; Viskin S
    J Am Coll Cardiol; 2001 Oct; 38(4):1168-74. PubMed ID: 11583899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy.
    Mattioni TA; Zheutlin TA; Sarmiento JJ; Parker M; Lesch M; Kehoe RF
    Ann Intern Med; 1989 Oct; 111(7):574-80. PubMed ID: 2774388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QT interval and drug therapy.
    Drug Ther Bull; 2016 Mar; 54(3):33-6. PubMed ID: 26966121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care.
    Roden DM; Woosley RL; Primm RK
    Am Heart J; 1986 Jun; 111(6):1088-93. PubMed ID: 3716982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
    Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G
    Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine.
    Vieweg WV; Schneider RK; Wood MA
    Acta Psychiatr Scand; 2005 Oct; 112(4):318-22; author reply 322. PubMed ID: 16156840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxifloxacin and torsade de pointes.
    Dale KM; Lertsburapa K; Kluger J; White CM
    Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained QT prolongation induced by tacrolimus in guinea pigs.
    Minematsu T; Ohtani H; Sato H; Iga T
    Life Sci; 1999; 65(14):PL197-202. PubMed ID: 10530807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia.
    Otsuka M; Kanamori H; Sasaki S; Taguchi J; Harano H; Ogawa K; Matsuzaki M; Mohri H; Okubo T; Sumita S; Ochiai H
    Intern Med; 1997 Oct; 36(10):705-8. PubMed ID: 9372331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.